AMOXICILLIN AND CLAVULANATE POTASSIUM tablet, film coated

Valsts: Amerikas Savienotās Valstis

Valoda: angļu

Klimata pārmaiņas: NLM (National Library of Medicine)

Aktīvā sastāvdaļa:

AMOXICILLIN (UNII: 804826J2HU) (AMOXICILLIN ANHYDROUS - UNII:9EM05410Q9), CLAVULANATE POTASSIUM (UNII: Q42OMW3AT8) (CLAVULANIC ACID - UNII:23521W1S24)

Pieejams no:

NuCare Pharmaceuticals, Inc.

Ievadīšanas:

ORAL

Receptes veids:

PRESCRIPTION DRUG

Ārstēšanas norādes:

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Amoxicillin and Clavulanate Potassium Tablets USP, Amoxicillin and Clavulanate Potassium for Oral Suspension USP, and Amoxicillin and Clavulanate Potassium Tablets USP (Chewable) and other antibacterial drugs, Amoxicillin and Clavulanate Potassium Tablets USP, Amoxicillin and Clavulanate Potassium for Oral Suspension USP, and Amoxicillin and Clavulanate Potassium Tablets USP (Chewable) should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Amoxicillin and Clavulanate Potassium Tablets USP, Amoxicillin and Clavulanate Potassium for Oral Suspension USP, and Amoxicillin and Clavulanate Potassium Tablets USP (

Produktu pārskats:

Amoxicillin and Clavulanate Potassium Tablets USP Amoxicillin and Clavulanate Potassium Tablets USP are supplied as follows: 875 mg/125 mg: White, capsule-shaped, biconvex, film-coated, scored tablets, debossed 93 on one side and 22 score line 75 on the other side. Each tablet contains 875 mg amoxicillin, USP as the trihydrate and 125 mg clavulanic acid as the potassium salt. They are available in bottles of 14 tablets (NDC 66267-712-14). Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required). Advise patients to keep in a closed container. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

Autorizācija statuss:

Abbreviated New Drug Application

Produkta apraksts

AMOXICILLIN AND CLAVULANATE POTASSIUM- AMOXICILLIN AND CLAVULANATE
POTASSIUM TABLET, FILM COATED
NUCARE PHARMACEUTICALS, INC.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
AMOXICILLIN AND CLAVULANATE POTASSIUM
TABLETS USP, AMOXICILLIN AND CLAVULANATE POTASSIUM FOR ORAL SUSPENSION
USP, AND AMOXICILLIN AND
CLAVULANATE POTASSIUM TABLETS USP (CHEWABLE) SAFELY AND EFFECTIVELY.
SEE FULL PRESCRIBING INFORMATION FOR
AMOXICILLIN AND CLAVULANATE POTASSIUM TABLETS USP, AMOXICILLIN AND
CLAVULANATE POTASSIUM FOR ORAL
SUSPENSION USP, AND AMOXICILLIN AND CLAVULANATE POTASSIUM TABLETS USP
(CHEWABLE).
AMOXICILLIN AND CLAVULANATE POTASSIUM TABLETS USP, AMOXICILLIN AND
CLAVULANATE
POTASSIUM FOR ORAL SUSPENSION USP, AND AMOXICILLIN AND CLAVULANATE
POTASSIUM TABLETS
USP (CHEWABLE) FOR ORAL USE INITIAL U.S. APPROVAL: 1984
TO REDUCE THE DEVELOPMENT OF DRUG-RESISTANT BACTERIA AND MAINTAIN THE
EFFECTIVENESS OF AMOXICILLIN AND
CLAVULANATE POTASSIUM TABLETS, AMOXICILLIN AND CLAVULANATE POTASSIUM
FOR ORAL SUSPENSION, AND AMOXICILLIN AND
CLAVULANATE POTASSIUM TABLETS (CHEWABLE) AND OTHER ANTIBACTERIAL
DRUGS, AMOXICILLIN AND CLAVULANATE POTASSIUM
TABLETS, AMOXICILLIN AND CLAVULANATE POTASSIUM FOR ORAL SUSPENSION,
AND AMOXICILLIN AND CLAVULANATE POTASSIUM
TABLETS (CHEWABLE) SHOULD BE USED ONLY TO TREAT INFECTIONS THAT ARE
PROVEN OR STRONGLY SUSPECTED TO BE CAUSED
BY BACTERIA.
INDICATIONS AND USAGE
Amoxicillin and Clavulanate Potassium Tablets USP, Amoxicillin and
Clavulanate Potassium for Oral Suspension USP, and
Amoxicillin and Clavulanate Potassium Tablets USP (Chewable) are
combination penicillin-class antibacterials and beta-
lactamase inhibitors indicated for treatment of the following:
Lower respiratory tract infections ( 1.1)
Acute bacterial otitis media ( 1.2)
Sinusitis ( 1.3)
Skin and skin structure infections ( 1.4)
Urinary tract infections ( 1.5)
DOSAGE AND ADMINISTRATION
Adults and Pediatric Patients > 40 kg: 500 mg/125 mg or 875 mg/125 mg
every 12 hours or 250 mg